Montreal, QC H4S 2A1
Full-time employees: 180
|Mr. Lloyd Mitchell Segal||Pres, CEO & Director||913.37k||148.07k||1964|
|Mr. Steve Forte||Exec. VP & CFO||608.52k||N/A||1979|
|Dr. Michael Zinda Ph.D.||Exec. VP & Chief Scientific Officer||655.28k||1.07M||1971|
|Dr. Maria Koehler M.D., Ph.D.||Exec. VP & Chief Medical Officer||669.83k||892.97k||1958|
|Dr. Daniel Durocher Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Frank Sicheri Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Agnel Sfeir Ph.D.||Co-Founder||N/A||N/A||N/A|
|Mr. Cameron Black||Exec. VP of Discovery||N/A||N/A||N/A|
|Dr. Kim A. Seth Ph.D.||Exec. VP & Chief Bus. Officer||N/A||N/A||N/A|
|Mr. Philip Herman||Exec. VP, Chief Commercial & Portfolio Devel. Officer||N/A||N/A||1980|
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Repare Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.